Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicines

• Date:
  Friday, 9 November 2018, All day
• Location:
  European Medicines Agency, Amsterdam, the Netherlands

At this multi-stakeholder meeting, representatives of patients, consumers and healthcare professionals and pharmaceutical industry stakeholders join regulators to discuss the work of the Heads of Medicines Agencies/EMA task force on the availability of medicines and how to contribute to its deliverables. The task force was set up to to provide strategic support and advice to tackle disruptions in supply of human and veterinary medicines and ensure their continued availability.

Attendance to this workshop is by invitation only, but all those interested are welcome to follow the live broadcast . A video recording and presentations will be published after the event.

Video recording

 

Documents

Report - Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicine

Agenda - Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicines

Reference Number: EMA/201498/2018

List of participants - Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicines

Reference Number: EMA/725241/2018

Presentation - Workshop objectives (K. Raudsepp)

Presentation - Availability of medicines: Impact on public health

Presentation - Medicines and vaccines shortages: a global concern (F. Blanco)

Presentation - Preparing for the unexpected: when your medicine is not available anymore (F. Houyez)

Presentation - Availability of medicines: Impact on public health (E. de Vries)

Presentation - How regulators are working to improve prevention and management of availability problems (K. Raudsepp)

Presentation - Prevention and management of availability problems: An industry perspective

Presentation - Impact of Brexit on medicines availability Centrally Authorised Products (CAPs) (M. Dias, I. Claassen)

Presentation - CMDh Brexit update (L. Oliveira, H. Hurts)

Presentation - Impact of Brexit on veterinary medicines availability (L. Le Letty)

Presentation - Industry stakeholders’ perspective: Impact of Brexit on medicines availability (Y. Stewart)

Presentation - Presentation from veterinary industry EU/EEA Brexit preparedness: status and impact (R. Clayton)

Presentation - Improving reporting and monitoring: EU-wide shortage definition and metrics (B. Cuddy, A. Hansen)

Presentation - Draft guidance for industry to improve reporting and best practice (B. Escribano, E. Martinez)

Presentation - Current public communication practices by regulators on medicines availability and shortages (Y. Knudsen)

Presentation - Best practice guidance for EU authorities on public communication (J. Burgos)

Presentation - Concluding remarks and next steps (N. Wathion)